Rocket Pharmaceuticals

175 articles about Rocket Pharmaceuticals

• Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress

  5/5/2022

  Rocket Pharmaceuticals, Inc. reports financial results for the quarter ending March 31, 2022, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.

• Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference

  4/27/2022

  Rocket Pharmaceuticals, Inc . today announces that Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, will deliver an in-person company presentation at the Bank of America Securities Healthcare Conference on Wednesday, May 11 at 2:20 p.m. ET.

• Rocket Pharmaceuticals to Present at Upcoming Investor Conferences

  3/29/2022

  Rocket Pharmaceuticals, Inc. today announces that Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, will deliver a virtual company presentation at the Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference on Friday, April 1 at 8:00 a.m. ET.

• Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors

  3/14/2022

  Rocket Pharmaceuticals, Inc. today announces the appointment of Fady Malik, M.D., Ph.D., to its Board of Directors.

• Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

  3/8/2022

  Rocket Pharmaceuticals, Inc. today announces the appointment of Jessie Yeung as Vice President of Investor Relations and Corporate Finance.

• 

  Rocket Pharma Sheds Light on Rare Form of Cardiomyopathy

  3/7/2022

  The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.

• Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

  2/24/2022

  Rocket Pharmaceuticals, Inc. today reports financial and operational results for the fourth quarter and year ended December 31, 2021.

• Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference

  2/10/2022

  Rocket Pharmaceuticals, Inc. announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET.

• Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs

  1/11/2022

  Rocket Pharmaceuticals, Inc. today shares expected milestones for 2022, which were discussed yesterday during the Company’s virtual presentation at the 40th Annual J.P. Morgan Healthcare Conference.

• 

  A Look at the Biggest Biopharma Stories of 2021

  1/6/2022

  Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.

• Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.

• Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

  12/13/2021

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), today announces positive clinical updates from its ongoing Phase 2 registrational trials for Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I) and its ongoing Phase 1 trial for Pyruvate Kinase Deficiency (PKD) at the 63rd American Society of Hematology (ASH) Annual Meeting.

• Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer

  12/8/2021

  Rocket Pharmaceuticals, Inc. today announces the appointment of Martin L. Wilson as General Counsel, Chief Compliance Officer and Senior Vice President.

• Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

  11/15/2021

  Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

• Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data

  11/11/2021

  Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data

• Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference

  11/10/2021

  Rocket Pharmaceuticals, Inc. today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET.

• Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021

  11/8/2021

  Rocket Pharmaceuticals, Inc. announces that updated data from the ongoing Phase 1 clinical trial of RP-A501 in Danon Disease will be presented at the American Heart Association Scientific Sessions 2021 taking place virtually November 13-15, 2021.

• Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting

  11/4/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces upcoming data presentations at the 63rd American Society of Hematology Annual Meeting taking place virtually and in Atlanta, Georgia from December 11-14, 2021.

• Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress

  11/3/2021

  Rocket Pharmaceuticals, Inc. today reports financial results for the quarter ending September 30, 2021 and updates on the Company's key pipeline developments, business operations, and upcoming milestones.

• Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

  10/20/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces interim data updates from the RP-L201 Phase 1/2 clinical trial for the treatment of Leukocyte Adhesion Deficiency-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy.